Arch. Dis. Child

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Archives of Disease in Childhood - Fetal and Neonatal Edition 2006;91:F153; doi:10.1136/adc.2004.066431
Copyright © 2006 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in ADC Online
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bot, P
Right arrow Articles by van der Stappen, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bot, P
Right arrow Articles by van der Stappen, J
Related Collections
Right arrow Pregnancy
Right arrow Drugs: psychiatry
Right arrow Adverse drug reactions
Right arrow Perinatal

LETTER

Neonatal effects of exposure to selective serotonin reuptake inhibitors during pregnancy

P Bot1, B A Semmekrot1, J van der Stappen2

1 Department of Paediatrics, Canisius-Wilhelmina Hospital, PO Box 9015, 6500 GS Nijmegen, the Netherlands
2 Department of Clinical Chemical Analysis, Canisius-Wilhelmina Hospital

Correspondence to:
Correspondence to:
Dr Semmekrot
B.Semmekrot@cwz.nl

Keywords: paroxetine; fluoxetine; sertraline; selective serotonin reuptake inhibitors; pregnancy

The first 150 words of the full text of this article appear below.

Selective serotonin reuptake inhibitors (SSRIs) are often prescribed during pregnancy.

It has long been debated whether adverse neonatal effects described after maternal SSRI use1–4 are caused by serotonin toxicity or withdrawal.5 Recently, the information of a database analysis of 93 suspected cases of SSRI induced neonatal withdrawal has been regarded as enough information to confirm a possible causal relation.6

We describe six infants with neonatal symptoms after maternal SSRI use. Table 1Go summarises data from these infants. Mothers in cases 1 and 4 used multiple drugs during pregnancy. Because neonatal withdrawal to clorazepate has been described as neurological depression, this agent may have played an additional role in the initial symptoms in case 1. Neither oxcarbazepine nor thyroxine are known to cause neonatal abstinence. Gastro-oesophageal reflux, observed in case 1, may contribute to feeding problems, but the infant’s symptoms decreased before the start of anti-reflux medication, suggesting multicausality.


View this table:
[in this window]
[in a new window]
 
Table 1  Patient data, . . . [Full text of this article]

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
ARCH DIS CHILD FETAL NEONATAL ED ED PRACTICE
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2006 BMJ Publishing Group Ltd & Royal College of Paediatrics and Child Health